News
Moderna's New Lower-Dose COVID-19 Vaccine Approved by FDA
By Stephanie Brown HealthDay ReporterTUESDAY, June 3, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2.
Moderna's new COVID-19 vaccine mNexspike approved by FDA, but there's a limit on who can use it
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective - and more by some measures - than the original shot, the company said.
Moderna convinced a U.S. appeals court on Wednesday to uphold a ruling that undercut patent infringement claims by biotech ...
Moderna (NASDAQ: MRNA) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from ...
Moderna had already started a Phase 1/2 trial of its bird flu (H5N1) vaccine and reported strong early results.
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Tuesday that Moderna has agreed to a true ...
The biotech giant that soared during Operation Warp Speed now faces regulatory hurdles, political scepticism, and dwindling ...
KEY TAKEAWAYS U.S. equities were mixed at midday after China accused the U.S. of violating a trade deal the two countries ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback